Vasopharm
Biopharmaceutical company developing treatments for traumatic brain injuries.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
€9.5m | Late VC | ||
| Total Funding | 000k | ||
| EUR | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Vasopharm, which now operates as veriNOS Pharmaceuticals, is a biopharmaceutical company that specializes in the research and development of treatments for cerebrovascular and cardiovascular diseases. The company is focused on developing small molecule therapeutics for the treatment of Traumatic Brain Injury (TBI). Its lead drug candidate is VAS203 (Ronopterin), a nitric oxide synthase inhibitor that has been investigated in clinical trials for its potential to improve outcomes in TBI patients.
The company's business model is centered on drug development, from discovery through to clinical trials and potential commercialization. Vasopharm was founded in 1998 as a spin-off from the University of Würzburg and has since raised a total of $24.3 million in funding over three rounds to support its research and development activities. The company targets the healthcare sector, specifically the neurocritical care market, with its therapeutic candidates.
Keywords: biopharmaceutical, neuroprotective, traumatic brain injury, cerebrovascular, cardiovascular, drug development, clinical trials, small molecules, nitric oxide, Ronopterin